4 results
Primary objective: To determine the effect of hyperbilirubinemia on systemic activation of the innate immune response induced by a lipopolysaccharide (LPS) challenge. Secondary Objective(s): - To determine if hyperbilirubinemia shifts the pro-anti…
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.